Neumora Therapeutics' Advancing Drug Pipeline Supports Buy Rating
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)
Buy Rating Affirmed for Edgewell Personal Care on Strong International Performance and Margin Improvement Potential
Gulfport Energy's Strong Q2 Financials and Strategic Initiatives Secure Buy Rating
Ichor Hldgs Analyst Ratings
Nevro Corp: Sell Rating Upheld Amid Financial Shortfalls and Strategic Uncertainties
Wells Fargo Reaffirms Their Hold Rating on ONE Gas (OGS)
Rapid7 Analyst Ratings
Veeco Instruments Analyst Ratings
Analysts Have Conflicting Sentiments on These Technology Companies: Power Integrations (POWI), Fortinet (FTNT) and Qualys (QLYS)
ACADIA Pharmaceuticals: Strong Buy Rating on Growth Prospects and Side Effect Management
Qualys Analyst Ratings
Buy Rating Affirmed for ACADIA Pharmaceuticals Amidst Mixed Sales Performance and Positive Long-Term Outlook
Optimistic Outlook for Arcosa Inc.: Strategic Acquisitions and Financial Maneuvers Underpin Buy Rating
Veracyte Price Target Raised to $31.00/Share From $27.00 by Needham
Press Release: Target Hospitality Reports Impressive Second Quarter 2024 Results With Continued Strong Operational Performance
Arcturus Therapeutics: Buy Rating Affirmed Amid Kostaive Launch and ARCT-810 Clinical Advancements
Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Celsius Holdings (CELH) and WK Kellogg Co (KLG)
Buy Rating Affirmed Amid Leadership Transition and Strong Growth Prospects for Fennec Pharmaceuticals
Barrington Adjusts Price Target on CRA International to $194 From $186, Maintains Outperform Rating